House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Gastroenterology

Crohn’s disease: management

NICE · 2019 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE guideline NG129, Crohn's disease: management, contains recommendations dated 2010 to 2019. This summary covers its main clinical decisions: inducing remission, infliximab and adalimumab, maintaining remission (including after ileocolonic resection), surgery for distal ileal disease and strictures, and bone density monitoring. Separate NICE technology appraisals cover ustekinumab and vedolizumab. Several drug uses were off-label as of May 2019.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Inducing remission

  • For a first presentation, or a single inflammatory exacerbation within a 12-month period, offer monotherapy with a conventional glucocorticosteroid (prednisolone, methylprednisolone or intravenous hydrocortisone) to induce remission. Consider enteral nutrition instead in children when there is concern about growth or side effects, and in young people when there is concern about growth. [1]
  • Consider budesonide for a first presentation or single exacerbation within 12 months. It applies to distal ileal, ileocaecal or right-sided colonic disease when conventional glucocorticosteroids are contraindicated, declined or not tolerated. Explain that budesonide is less effective but may have fewer side effects. Use in children and young people was off-label in May 2019. [1]
  • Consider an aminosalicylate in the same 12-month scenario if conventional glucocorticosteroids are contraindicated, declined or not tolerated. Explain that it is less effective than a conventional glucocorticosteroid or budesonide, but may have fewer side effects than a conventional glucocorticosteroid. [1]
  • Do not offer budesonide or aminosalicylates for severe presentations or exacerbations. Do not offer azathioprine, mercaptopurine or methotrexate as monotherapy to induce remission. [1]
  • Consider adding azathioprine or mercaptopurine to a conventional glucocorticosteroid or budesonide to induce remission if there are 2 or more inflammatory exacerbations within 12 months, or if the glucocorticosteroid dose cannot be tapered. When the same triggers apply, consider adding methotrexate instead (following BNF and BNFC cautions) for people who cannot tolerate azathioprine or mercaptopurine, or whose TPMT activity is deficient. [1]
  • Assess TPMT activity before offering azathioprine or mercaptopurine. Do not offer them if activity is deficient (very low or absent). If activity is below normal but not deficient according to local laboratory reference values, consider them at a lower dose. [1]
  • Monitor azathioprine, mercaptopurine and methotrexate as the BNF or BNFC advises, consulting the monographs of individual drugs. Monitor for neutropenia on azathioprine or mercaptopurine even when TPMT activity is normal. [1]

Infliximab and adalimumab

  • Within their licensed indications, infliximab and adalimumab are recommended options for adults with severe active disease that has not responded to conventional therapy (including immunosuppressive and corticosteroid treatments), or when the person is intolerant of or has contraindications to conventional therapy. Only clinicians experienced with TNF inhibitors and with managing Crohn's disease should start and review them. [1]
  • Give infliximab or adalimumab as a planned course until treatment failure (including the need for surgery) or until 12 months after starting, whichever is shorter. Then reassess the disease to determine whether ongoing treatment is still clinically appropriate. [1]
  • Within its licensed indication, infliximab is a recommended option for active fistulising disease that has not responded to conventional therapy (including antibiotics, drainage and immunosuppressive treatments), or when the person is intolerant of or has contraindications to it. Give a planned course until treatment failure (including the need for surgery) or 12 months after starting, whichever is shorter, then reassess the disease. [1]
  • Within its licensed indication, infliximab is recommended for people aged 6 to 17 years with severe active disease that has not responded to conventional therapy (including corticosteroids, immunomodulators and primary nutrition therapy), or when the person is intolerant of or has contraindications to it. Review the need to continue at least every 12 months. [1]
  • For this guidance, severe active disease means very poor general health and one or more symptoms such as weight loss, fever, severe abdominal pain and usually frequent (3 to 4 or more) diarrhoeal stools daily. This normally, but not exclusively, corresponds to a CDAI score of 300 or more, or a Harvey-Bradshaw score of 8 to 9 or above. [1]
  • Continue infliximab or adalimumab only if there is clear evidence of ongoing active disease. This is determined by clinical symptoms, biological markers and investigation, including endoscopy if necessary. [1]
  • Specialists should discuss the risks and benefits of continued treatment and consider a trial withdrawal for all patients in stable clinical remission. Reassess those who continue at least every 12 months. People whose disease relapses after stopping should have the option to restart. [1]
  • When starting infliximab or adalimumab, discuss monotherapy versus combined therapy with an immunosuppressant. Tell the person that the comparative effectiveness and long-term adverse effects of the two approaches are uncertain. [1]

Maintaining remission

  • With people in remission, and their family or carers as appropriate, discuss management options including both no treatment and treatment. Cover the risk of inflammatory exacerbations with and without drug treatment, and the potential side effects, and record the person's views. [1]
  • When people choose not to have maintenance treatment, agree follow-up plans, including frequency, with them and their family or carers as appropriate. Ensure they know which symptoms should prompt consultation (most often unintended weight loss, abdominal pain, diarrhoea or general ill-health) and how to access care if they relapse. Discuss the importance of not smoking. [1]
  • Offer azathioprine or mercaptopurine monotherapy for maintenance when it was used with a conventional glucocorticosteroid or budesonide for induction. In people who have not received these drugs before, consider them, particularly with adverse prognostic factors such as early onset, perianal disease, glucocorticosteroid use at presentation or severe presentation. Do not offer conventional glucocorticosteroids or budesonide for maintenance. [1]
  • Consider methotrexate (following BNF and BNFC cautions) for maintenance only in three groups: people who needed it to induce remission, people who tried but did not tolerate azathioprine or mercaptopurine for maintenance, and people with contraindications to these drugs (for example deficient TPMT activity or previous pancreatitis). [1]

Maintaining remission after surgery

  • After complete macroscopic resection of ileocolonic disease within the last 3 months, consider azathioprine with up to 3 months' postoperative metronidazole to maintain remission. Consider azathioprine alone if metronidazole cannot be tolerated. The committee rationale states that these recommendations apply when there is no residual active disease. For people who still have residual active disease after surgery, the disease is not in remission and the induction recommendations apply. [1]
  • Do not offer biologics or budesonide to maintain remission after complete macroscopic resection of ileocolonic disease. [1]

Surgery, strictures and bone health

  • For disease limited to the distal ileum, consider surgery early in the disease course as an alternative to medical treatment, weighing recurrence risk and individual preferences. For children and young people with distal ileal disease, consider surgery early, or before or early in puberty, if growth is impaired despite optimal medical treatment and/or the disease is refractory. [1]
  • Consider balloon dilation for strictures, particularly when there is a single stricture that is short, straight and accessible by colonoscopy. [1]
  • Crohn's disease is a cause of secondary osteoporosis; assess adult fragility fracture risk using the NICE osteoporosis risk assessment guideline. Do not routinely monitor bone mineral density in children and young people. Consider monitoring in those with risk factors such as low BMI, low trauma fracture or continued or repeated glucocorticosteroid use. [1]

Limitations and use

  • This is a selective summary of the NG129 clinical recommendations. It does not detail several source sections: information and support (section 1.1), conception and pregnancy (section 1.7), the choice of the less expensive anti-TNF drug, score adjustment for disability, local safety-monitoring policies, colonoscopic surveillance, stricture assessment factors and the availability of surgery, postoperative azathioprine and metronidazole monitoring, and continuation of biologics started after surgery before May 2019.
  • Research recommendations and most committee rationale sections are not included.
  • Ustekinumab and vedolizumab are addressed only by referral to separate NICE technology appraisals, which are not summarised here.
  • Several uses of thiopurines, methotrexate, budesonide, aminosalicylates and metronidazole were off-label as of May 2019.
  • The postoperative recommendations apply only to ileocolonic disease after complete macroscopic resection with no residual active disease. None of the included studies looked specifically at children and young people after surgery, so the committee made no separate recommendations for them. The committee noted that, in its experience, children and young people are offered the same post-surgery treatment as adults.
  • Detailed drug monitoring defers to the BNF/BNFC, and adult fracture-risk assessment defers to another NICE guideline. Appendix observational data are not reproduced.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Crohn’s disease: management

    Guideline recommendation text consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
3 May 2019
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Inducing remission
  • Infliximab and adalimumab
  • Maintaining remission
  • Maintaining remission after surgery
  • Surgery, strictures and bone health
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House